[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571743":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":34,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":7,"maxAge":44,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Rita Ortolano, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":15,"email":16},"CONTACT","0512144816","rita.ortolano@aosp.bo.it",[18],{"facility":5,"status":19,"city":20,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Bologna","40138","Italy","IT",{"type":25,"coordinates":26},"Point",[27,28],11.33875,44.49381,{"lat":28,"lon":27},[31,33],{"name":10,"role":14,"phone":32,"phoneExt":7,"email":16},"0039 0512144816",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":11,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Rita Ortolano","MD","100571743","comparison-of-levothyroxine-formulations-in-the-treatment-of-congenital-hypothyroidism-100571743",false,"NCT06724224","Comparison of Levothyroxine Formulations in the Treatment of Congenital Hypothyroidism","Inclusion Criteria:\n\nNewborn screening test positivity for Congenital Hypothyroidism; Subjects born in Emilia-Romagna region, Italy, and undergoing diagnostic confirmation and initiation of replacement therapy; Diagnosis-confirmed subjects who underwent L-T4 replacement therapy in the first month of life at Center for Endocrine-Metabolic Diseases, Pediatrics Units of the IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di S.Orsola, Italy; Age ≤11 years old; Obtaining informed consent from parents and\u002For legal guardians and assent from minors included in the study.\n\nExclusion Criteria:\n\nKnown chromosomal abnormalities or complex syndromes; Patients transferred to another center before completion of at least one year of follow-up from the start of therapy; Patients who started therapy at another center.","ALL","11 Years",{"count":46,"type":47},120,"ESTIMATED","OBSERVATIONAL","Observational, retrospective, prospective, pharmacological, single-centre, non-profit study.\n\nThe aim is to evaluate, in newborns diagnosed with Congenital Hypothyroidism, the medium- and long-term efficacy and safety of the new formulation of levothyroxine in oral solution, compared to the liquid drop formulation and the tablet formulation.\n\nThe study will involve male and female patients referred to the Neonatal Screening Centre at the Centre for Endocrine-Metabolic Diseases of the Paediatrics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di S. Orsola, Italy, who tested positive for Congenital Hypothyroidism.",[51],"Congenital Hypothyroidism","2026-03-11",{"date":54,"type":55},"2026-03-12","ACTUAL",{"date":57,"type":55},"2024-04-08",{"date":59,"type":47},"2031-10-08",{"name":5,"class":6},1]